Business Wire

CA-SCIENTIST.COM

23.3.2022 17:20:10 CET | Business Wire | Press release

Share
LIDE Biotech Participates in VERIF.i®, Scientist.com’s Supplier Pre-assessment Program, to Support Continued Growth in North America and the EU

Scientist.com, the pharmaceutical industry’s leading R&D marketplace, announced today that VERIF.i® , the company’s supplier pre-assessment program, has been used to successfully complete an on-site assessment of the LIDE Biotech facility in Shanghai, China. VERIF.i was developed to help users on both sides of the Scientist.com marketplace improve quality standards and reduce indirect costs.

LIDE (Lab for Innovated Diagnosis and Experimental Therapeutics) Biotech is a translational medicine service provider that has delivered innovations in oncology translational research and immune-oncology for the past 11 years. LIDE was founded by overseas returnees Drs. Danyi Wen, Yizhun Zhu and others, with the goal of bringing together first-class research and management teams with advanced scientific backgrounds to push the frontier of translational medical research. LIDE is committed to superior research quality; in 2015, it partnered with several large pharma and biotech companies to create a PDX Consortium Board with the goal of promoting and ensuring high PDX standards across China.

“At LIDE we hold ourselves to the highest industry standards by ensuring superior quality of our facilities and the world class scientists operating them,” stated Dr. Danyi Wen, President and CEO of LIDE Biotech. “Together with other industry certifications, VERIF.i allows us to showcase our quality commitment across the industry in North America and Europe as well as in the growing Scientist.com marketplace.”

VERIF.i gives suppliers of regulated research services the opportunity to proactively communicate their standards against pre-defined criteria developed for the biopharma industry and then confirm them through independent, third-party auditors that carry out an on-site inspection. Pre-assessments help suppliers such as LIDE Biotech demonstrate their quality and capabilities, while also helping pharma and biotech customers purchase regulated services in an accelerated manner with more confidence and less risk.

“Even prior to the Covid-19 pandemic, on-site assessments of laboratories were difficult to complete owing to the high cost and intensive resource and time requirements,” stated Matt McLoughlin, SVP of Categories and Compliance at Scientist.com . “VERIF.i addresses these challenges by creating a standardized process for both customers and suppliers. It also enables suppliers like LIDE to differentiate themselves from their peers by sharing independent insight into their facilities, personnel and processes."

VERIF.i is an expansion of Scientist.com’s award-winning COMPLi® solution. For more information visit https://www.scientist.com/verifi/

About LIDE Biotech

LIDE biotech is committed to accelerating translation from pre-clinical to clinical for our clients. We do this through our unique access to fresh patient samples, received daily via our close hospital partnerships across China. These relationships combined with our proprietary kits, tumor sample kit, CRC kit, MiniPDX assay kit, and K-Cell kits, LIDE’s platform gives our clients the competitive edge to save time and budget. Based on this success, LIDE has built a robust database of over 1600+ PDX, CDX, and Cell Line models which grows daily. Our CRO services can be custom tailored based on what stage of the pre-clinical oncology drug development process you’re in, including clinical biopsy collection, in vitro/in vivo studies, transcription RNA and DNA analysis, and Immuno-Oncology capabilities.

LIDE Biotech will be at the American Association for Cancer Research Annual Meeting in New Orleans from April 10 – 13. Stop by First Floor Exhibit Hall D-H, Booth # 2057.

Watch LIDE Biotech’s Director of Immuno-Oncology, Dr. Bin Xie discuss current and novel Immuno-Oncology drug evaluation methods via humanized mouse models on a Scientist.com-hosted webinar.

Visit www.lidebiotech.com to learn more and follow updates on the LIDE Biotech LinkedIn page.

About Scientist.com

Scientist.com’s mission is to empower and connect scientists worldwide. By transforming the way scientific research is performed, our Science as a Service® platform accelerates discoveries that prevent and cure disease, address climate change and help secure global food and energy supplies. We combine sophisticated AI technology with white-glove Research Concierge® support to enable scientists to run more innovative experiments in less time and at lower cost.

Visit scientist.com to learn more.

Join Scientist.com on social media: LinkedIn , Twitter , YouTube , Facebook and Instagram

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents23.4.2026 13:29:00 CEST | Press release

Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agentsA manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designationThe program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by t

Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press release

New structure to drive AI-powered innovation and international expansion Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency

NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce23.4.2026 13:00:00 CEST | Press release

NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time. AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them. AI is Becoming the Operating Layer of Global Commerce NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what product

Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights23.4.2026 12:10:00 CEST | Press release

Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues,

REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements23.4.2026 12:05:00 CEST | Press release

Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);Group net profits of €250.9 million (€211.1 million in 2024).Approval of the proposal to distribute a dividend of €1.35 per share.Approval of the plan for the purchase and/or disposal of treasury shares. The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared to €2,300.5 million in 2024. Consolidated EBITDA was €467.6 million, up 13.9% compared to €410.6 million recorded for the year 2024. EBIT, from January to December, was €397.1 million, up 18.5% compared to €330.4 million recorded for

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye